15 citations
,
October 2015 in “PLOS ONE” The Chinese version of the PCOS quality of life questionnaire is reliable and valid for Chinese-speaking women with PCOS.
November 2013 in “International Society of Hair Restoration Surgery”
1 citations
,
May 2025 in “International Journal of Applied Pharmaceutics” The nanogel with Bangkal bark extract effectively fights acne-causing bacteria.
13 citations
,
January 2010 in “Immunopharmacology and immunotoxicology” Diphencyprone increases Bcl-2 protein in patients with hair regrowth from alopecia areata.
8 citations
,
August 2021 in “Aging” Berberine may reduce prostate enlargement by blocking inflammation.
March 2014 in “International Society of Hair Restoration Surgery” 49 citations
,
January 2024 in “Regenerative Biomaterials” The new nanofiber patch speeds up diabetic wound healing and improves healing quality.
November 2024 in “Medicina Estética Revista Científica de la Sociedad Española de Medicina Estética (SEME)” La detección temprana y precisa de la pseudopelada de Brocq es crucial para detener su progresión.
March 2026 in “Frontiers in Cell and Developmental Biology” Photobiomodulation may help reduce pain and inflammation in knee osteoarthritis, but its long-term benefits are unclear.
1 citations
,
January 1986 in “PubMed” The boy's symptoms suggest a possible new medical condition.
September 2024 in “Journal of Medicine and Life” A specific gene mutation causes a severe skin disorder in a family.
10 citations
,
November 2022 in “Protein & Cell” Quercetin significantly helps hair growth by activating hair follicles and improving blood vessel formation around them.
15 citations
,
March 2008 in “The Journal of Dermatology” Topical squaric acid dibutylester worsened discoid lupus erythematosus in a patient.
9 citations
,
January 2018 in “Acta Clinica Croatica” Bendamustine, often combined with other drugs, is effective and less toxic for certain blood cancers, but less effective for young, fit patients with CLL.
2 citations
,
January 2023 in “Skin Appendage Disorders” Beard alopecia areata causes patchy beard hair loss, often treatable with janus kinase inhibitors.
November 2022 in “Journal of the Endocrine Society” Diagnosing osteoporosis in transgender people is challenging due to unclear guidelines and hormone treatment effects.
December 2025 in “Journal of Skin and Sexually Transmitted Diseases” 1 citations
,
April 2024 in “The Journal of Dermatology” Untreated epidermolysis bullosa acquisita can cause total hair and nail loss.
October 2023 in “Open Repository of the University of Porto (University of Porto)” Pharmacists play a key role in health education and managing treatments for conditions like hair loss and smoking cessation.
April 2023 in “Journal of Investigative Dermatology” Long-term Imiquimod treatment causes initial skin inflammation that lessens over time, and topical corticosteroids reduce this inflammation and cytokines in a mouse model of psoriasis.
2 citations
,
August 2016
November 2022 in “Journal of Drug Delivery and Therapeutics” Unani medicine links diffuse hair loss to poor skin pore function and body dryness, leading to thinning hair.
April 2017 in “Journal of Investigative Dermatology” Targeted siRNA therapy may be a promising treatment for KID syndrome by reducing mutant gene expression and improving cell communication.
Baricitinib effectively promotes regrowth of eyebrows and eyelashes in alopecia areata patients.
76 citations
,
July 2019 in “Scientific Reports” Baicalin nanocapsules greatly enhance its anticancer effects on breast cancer cells.
39 citations
,
January 2023 in “Journal of the European Academy of Dermatology and Venereology” Alopecia areata significantly worsens quality of life in children, causing embarrassment and social issues.
July 2009 in “Planta Medica” Traditional healers in Pabna, Bangladesh, use various plants to treat different health issues.
February 2024 in “ACS Omega” The Shen Bai Hair Growing Decoction may help treat hair loss by promoting hair growth and reducing inflammation.
60 citations
,
August 2022 in “ESMO Open” Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.